Thus, our finding supporting a different sensitivity between CD16/FcγRIIIA activation and triggering mediated by activating NK cell receptors is of relevance, as in the tumor microenvironment higher concentration of a drug can be achieved using appropriate drug-delivery systems [47]. The gene discussed is FCGR3A; the disease is neoplasm.